

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**

**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT  
UNUSUAL PRICE MOVEMENT**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company has noted the recent decrease in the price of the shares of the Company and having made such enquiry with respect to the Company as is reasonable in the circumstances, the Company hereby informs shareholders of the Company (the “**Shareholders**”) and potential investors that:

- (i) the Company is not aware of any specific reasons for such price movement or of any information which must be announced to avoid a false market in the shares of the Company or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and
- (ii) the Company is under normal operation and the management team of the Company has full confidence in the future development of the Company.

**Shareholders and potential investors should exercise caution when investing in or dealing in the securities of the Company.**

For and on behalf of  
**CanSino Biologics Inc.**  
**Xuefeng YU**

*Chairman and chief executive officer*

Hong Kong, June 4, 2019

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Dr. Zheng YIN as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.*